Savara Inc.: Orphan lung disease co. Molgradex, Ph 3, inhaled GM-CSF: autoimmune pulmonary alveolar proteinosis (aPAP), Ph 2a: nontuberculous mycobacteria (NTM) lung infection, and prep for Ph 2a in CF affected individuals w chronic NTM lung infection; and AeroVanc, Ph 3 inhaled vancomycin for persistent MRSA lung infection in CF. Expanding pipeline through indication expansion, strategic devt partnerships and product acqs. Most recent acquisition is aerosolized amikacin/fosfomycin, Phase 2 ready, proprietary combination antibiotic (demonstrated potent and broad-spectrum antibacterial activity against highly drug resistant pathogens).
Based in...
Clinical Stage
Phase III
Disease Space
Fibrosis, Rare Disease, Respiratory
Biotechnology, Life Sciences
Public, USA
Market Cap
6836 Bee Cave Road
Building 3, Suite 200
Austin, TX 78746
United States

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Upcoming Company Event Participation

Hamptons CEO Roundtable 2019

Bridgehampton, August 15, 2019

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2017 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.